NeuroSense Therapeutics (NRSN) Projected to Post Quarterly Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSN) is expected to release its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.1050) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Monday, April 6, 2026 at 4:00 PM ET.

NeuroSense Therapeutics Price Performance

Shares of NRSN opened at $0.75 on Monday. NeuroSense Therapeutics has a one year low of $0.68 and a one year high of $2.60. The stock’s fifty day moving average is $0.92 and its 200-day moving average is $1.02.

Wall Street Analyst Weigh In

Several research firms have commented on NRSN. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research note on Tuesday, March 17th. Roth Mkm began coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective for the company. Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, NeuroSense Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $8.50.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics in the second quarter worth approximately $54,000. Squarepoint Ops LLC lifted its position in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth $26,000. 1.04% of the stock is owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.